Sangamo Therapeutics Files for Chapter 11 Bankruptcy Amid Asset Sales and Major Restructuring.

Sangamo Therapeutics Inc. (SGMO) undergoes a significant restructuring as it files for Chapter 11 bankruptcy protection, a strategic move to divest certain assets under court supervision.

Sangamo's Bankruptcy and Asset Sales

This decision arrives in the wake of asset purchase agreements with prominent pharmaceutical companies, notably Eli Lilly and Co. and Astellas Pharma Inc. Under these plans, Eli Lilly proposes an acquisition worth up to $50 million, focusing on key technologies pivotal for Sangamo's innovations, including the AAV capsid engineering and the Modular Integrase genome editing platforms. Meanwhile, Astellas Pharma looks to purchase Sangamo’s investigational treatment for Fabry disease, known as isaralgagene civaparvovec, for an initial $25 million, with additional payments contingent on specific milestones being reached.

Financial Stability through Financing

To manage its operations through this challenging period, Sangamo has obtained up to $30 million in debtor-in-possession financing, pending court approval. This funding is intended to stabilize the company's financial situation while pursuing the asset sales and ongoing research programs.

Impact on Workforce and Future Prospects

Additionally, the company braces for significant workforce reductions, projecting a 40% decrease in its workforce, which translates to approximately 51 layoffs, leaving around 77 employees to continue critical work aligned with existing programs. These restructuring efforts underscore the gravity of Sangamo's situation as it addresses financial pressures while trying to retain crucial projects and partnerships with Eli Lilly and Astellas.

Overall, the bankruptcy filing represents a pivotal moment for Sangamo Therapeutics, revealing its strategic pivot in response to evolving challenges within the biopharmaceutical landscape.